Asthma: Chronopharmacotherapy and the molecular clock

Naoto Burioka, Yasushi Fukuoka, Satoru Koyanagi, Masanori Miyata, Miyako Takata, Hiroki Chikumi, Hiroshi Takane, Masanari Watanabe, Masahiro Endo, Takanori Sako, Hisashi Suyama, Shigehiro Ohdo, Eiji Shimizu

Research output: Contribution to journalReview articlepeer-review

46 Citations (Scopus)


Bronchial asthma is characterized by chronic airways inflammation and reversible airflow limitation. In patients with asthma, symptoms generally worsen during the early hours of the morning, and pulmonary function often deteriorates at the same time, suggesting a role for chronopharmacotherapy. Several drugs for asthma have been developed based on chronopharmacology. Most medications employed for the chronotherapy of asthma are administered once at night with the goal of preventing chronic airway inflammation or development of airflow limitation. In addition to bronchodilators, the inhaled glucocorticosteroid ciclesonide is now available with once-daily dosing, which also improves patients' compliance. Numerous investigations have demonstrated the usefulness of chronotherapy for asthma, especially for patients with nocturnal asthma. This review focuses on chronotherapy of asthma, and also provides a molecular biological explanation for the influence of asthma medications on the clock genes.

Original languageEnglish
Pages (from-to)946-955
Number of pages10
JournalAdvanced Drug Delivery Reviews
Issue number9-10
Publication statusPublished - Jul 2010

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science


Dive into the research topics of 'Asthma: Chronopharmacotherapy and the molecular clock'. Together they form a unique fingerprint.

Cite this